FYI
The following may be of interest compiled from the latest Acadia update:
*1250 patients [25.0%] of the currently identified Retts patients in the US have been treated with Daybue.
*862 patients from the above group are currently being treated with Daybue leaving 388 patients [31.0%] no longer under treatment. This is a minimum drop- out rate as it includes all the new patients enrolled in the past 6 weeks.
*QI 2024 revenue was down 12.8% compared to Q4 2023 for a variety of subjective reasons.This is more than the revenue guidance miss suggests.
*According to Neuren gross to net discounting was higher in Q1 2024 than the previous quarter. No guide as to split between the Insured/Medicaid [discounted] patients has been indicated. Culper did not even mention discounting as a downside issue.
*Using the Q1 2024 revenue of $75.9M as a base Daybue sales have to increase in 9 months by between 21.9% and 38.3% off that base number to meet Acadias full year revenue guidance.
Kens
Neuren Media and Analyst Coverage, page-954
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.80 |
Change
0.300(1.54%) |
Mkt cap ! $2.528B | |||
| Open | High | Low | Value | Volume |
| $19.49 | $19.92 | $19.25 | $5.352M | 271.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $19.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.80 | 516 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.80 |
Change
0.300 ( 0.98 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.92 | $19.25 | 77870 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| NEU (ASX) Chart |
